Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.
ELEM Biotech
Grant in 2022
ELEM is a start-up company conceived at the Barcelona Supercomputing Center (BSC) and host of MareNostrum supercomputer. ELEM is co-founded by BSC researchers Mariano Vázquez, Guillaume Houzeaux, José María Cela, and business consultant Chris Morton. The company has developed Alya Red, a set of simulation tools, which following a “Software-as-a-Service” model deployed in the cloud, focuses on medical devices and pharmaceutical industries. Alya Red simulates cardiovascular or respiratory systems on “virtual patients”. Combining high performance computing, computational biomechanics and data analysis, these computational avatars can be used by biomedical sector companies and clinicians to elaborate diagnoses, plan treatments, improve drug delivery and action, optimise medical devices, etc. ELEM headquarters are in Barcelona.
Methinks Software, founded in 2016 and based in Barcelona, Spain, specializes in developing artificial intelligence medical software focused on stroke diagnosis and treatment. Utilizing advanced techniques from Google's deep learning framework, TensorFlow, the company analyzes neuroimaging to provide timely and accurate diagnoses of brain-related diseases, particularly acute strokes. Its medical imaging platform enables rapid assessment from non-contrast CT scans, streamlining the diagnosis process and facilitating improved communication between radiologists, hospitals, stroke units, and healthcare professionals. By bypassing the need for contrast CT scans, Methinks aims to reduce time-to-treatment, ultimately enhancing clinical outcomes and patient care in emergency settings.
Tucuvi Care, S.L. is a Madrid-based company that specializes in developing artificial intelligence and voice technology solutions for the healthcare sector. Founded in 2019, Tucuvi's platform serves a variety of clients, including hospitals, insurance companies, telecare services, and patient associations. The company offers an intelligent virtual caregiver designed to support older adults in maintaining their independence at home. Its technology provides personalized care through features such as medication reminders, treatment guidelines, cognitive stimulation exercises, and assessments of caregiver satisfaction. Additionally, Tucuvi's platform aids healthcare professionals by enhancing their ability to monitor and care for patients, particularly those with chronic conditions like heart failure.
Ignion is an antenna innovator that creates a multiband, multipurpose and ready-to-use antenna. The company was founded in 2015 and is based in Sant Cugat del Vallès, Spain.
Ignion is an antenna innovator that creates a multiband, multipurpose and ready-to-use antenna. The company was founded in 2015 and is based in Sant Cugat del Vallès, Spain.
New Born Solutions is a medical device company that provides non-invasive screening for infant meningitis.
New Born Solutions is a medical device company that provides non-invasive screening for infant meningitis.
Saalg Geomechanics is owner and operator of an engineering company intended to offer specialized advanced geological and numerical services. The company offers numerical model calibrations and soil and rock parameters characterization by backanalysis and inverse analysis, 2D and 3D geomechanical and geotechnical simulations, manily for TBM Tunnel Excavations, Conventional Tunnels, Large and deep excavations, reinforced earth retaining walls and wellbore stabity analysis, enabling their customers to build a bridge between academic research in the field of geomechanics and the industry.
Amadix is focused on developing and commercializing innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company's flagship product, Colofast, is a non-invasive screening signature for colorectal cancer and advanced adenoma diagnosis, aimed at reducing the high mortality rate associated with colon cancer. Amadix's approach emphasizes early detection, allowing for timely treatment while avoiding the complications of invasive procedures like tumor biopsies. The team comprises industry veterans with extensive expertise in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by independent board members who provide strategic guidance in commercialization and business development, particularly in Europe and the United States. Amadix's products undergo rigorous analytical validation and clinical studies before being introduced to the global market.
Multiverse Computing SL develops software for the finance industry. It develops software for solving financial and macro-economic problems. The company was incorporated in 2019 and is based in San Sebastian, Spain with an additional office in Toronto, Canada.
Multiverse Computing SL develops software for the finance industry. It develops software for solving financial and macro-economic problems. The company was incorporated in 2019 and is based in San Sebastian, Spain with an additional office in Toronto, Canada.
From smartphones to connected cars, location data is changing the way we live and the way business happens. CARTO is the platform that turns spatial data into more efficient delivery routes, better behavioral marketing, strategic store placements, and much more. Data Scientists, Developers, and Analysts solve spatial problems using CARTO’s data and analysis to understand where and why things happen, optimize business processes, and predict future outcomes through the power of Spatial Data Science. Backed by leading VC firms Accel Partners, Salesforce Ventures, Earlybird Ventures, and Kibo Ventures, CARTO is the world’s leading Location Intelligence platform. Founded in 2012 by an environmental scientist and visualization experts, CARTO is headquartered in New York City with offices in Madrid, Seville and Washington DC. CARTO has a team of 130 employees, a portfolio of 2,500 customers including BBVA, BCG, New York City, and Twitter and more than 350,000 users around the globe - and has regularly been recognized by Gartner and Forrester for its innovation in the Location Intelligence space.
Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable insights for various sectors, including academic research, plant and animal breeding, and biomedicine. Sequentia collaborates with over 30 public and private research centers, universities, and companies, participating in more than 160 research and development projects. The company offers a range of services, including cloud software, custom software solutions, and bioinformatics consulting, aimed at advancing healthcare, agriculture, and environmental sciences. Sequentia Biotech also maintains two open-source biodata banks and has developed an award-winning research initiative called Tricopharming. The founders have contributed significantly to the field, with over 40 scientific publications in prestigious journals.
Palobiofarma S.L. is a biotechnology company based in Barcelona, Spain, with an additional facility in Navarra. Founded in 2005, the company specializes in the discovery and development of new drugs that target adenosine receptors, with a focus on treating advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, Palobiofarma aims to be the first European company to market a selective adenosine receptor modulator, addressing significant medical needs through innovative therapeutic approaches.
MYSPHERA SL specializes in providing innovative location and process visibility solutions for the healthcare sector through the Internet of Things (IoT) and real-time location systems (RTLS). Founded in 2012 and based in Paterna, Spain, the company develops a range of IoT devices and applications designed to enhance patient care and resource management in acute care hospitals, senior living facilities, and patient homes. Its offerings include tracking devices, alert systems, and environmental sensors, along with web applications such as MYHOSPITAL, MYNURSING, and MYLOCS, which assist healthcare providers in managing services effectively. MYSPHERA's solutions aim to improve patient outcomes and operational efficiency by delivering actionable information to clinicians, patients, and healthcare management across Europe, the Middle East, and Latin America.
MYSPHERA SL specializes in providing innovative location and process visibility solutions for the healthcare sector through the Internet of Things (IoT) and real-time location systems (RTLS). Founded in 2012 and based in Paterna, Spain, the company develops a range of IoT devices and applications designed to enhance patient care and resource management in acute care hospitals, senior living facilities, and patient homes. Its offerings include tracking devices, alert systems, and environmental sensors, along with web applications such as MYHOSPITAL, MYNURSING, and MYLOCS, which assist healthcare providers in managing services effectively. MYSPHERA's solutions aim to improve patient outcomes and operational efficiency by delivering actionable information to clinicians, patients, and healthcare management across Europe, the Middle East, and Latin America.
A word About US.A bunch of visionary people. Scientific scouts. Daring entrepreneurs. Just a crew of dreamers, all with a common goal. Improving Human Experience.They give a Key to interact with the world through your imagination & our technology. Is a new way to play with the environment. Mountains. Trees. Clouds. Flowers. Rivers. Rocks. Animals. Waves. People. Friends. And a new way to show your feelings. flying, exploring, Surfing & Underwater.
Simplicity Works develops its patented technology 3D Bonding - the simplest method for joining pieces.
Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable insights for various sectors, including academic research, plant and animal breeding, and biomedicine. Sequentia collaborates with over 30 public and private research centers, universities, and companies, participating in more than 160 research and development projects. The company offers a range of services, including cloud software, custom software solutions, and bioinformatics consulting, aimed at advancing healthcare, agriculture, and environmental sciences. Sequentia Biotech also maintains two open-source biodata banks and has developed an award-winning research initiative called Tricopharming. The founders have contributed significantly to the field, with over 40 scientific publications in prestigious journals.
Palobiofarma S.L. is a biotechnology company based in Barcelona, Spain, with an additional facility in Navarra. Founded in 2005, the company specializes in the discovery and development of new drugs that target adenosine receptors, with a focus on treating advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, Palobiofarma aims to be the first European company to market a selective adenosine receptor modulator, addressing significant medical needs through innovative therapeutic approaches.
A word About US.A bunch of visionary people. Scientific scouts. Daring entrepreneurs. Just a crew of dreamers, all with a common goal. Improving Human Experience.They give a Key to interact with the world through your imagination & our technology. Is a new way to play with the environment. Mountains. Trees. Clouds. Flowers. Rivers. Rocks. Animals. Waves. People. Friends. And a new way to show your feelings. flying, exploring, Surfing & Underwater.
Roka Furadada mission is to reduce the incidence of skin cancer through research, development, and production of active ingredients and medical devices, with high efficiency and low toxicologic and environmental impact.
bound4blue specializes in the development of innovative foldable and autonomous wingsail systems designed for integration into a variety of vessels. This technology serves as a complementary propulsion system, harnessing wind power to generate thrust and significantly reducing the reliance on main engine power. As a result, bound4blue's wingsails can lead to reductions in fuel consumption and pollutant emissions by up to 40%. In addition to improving environmental sustainability, the system offers a payback period of less than five years, making it an economically viable option for boat operators. The technology also facilitates the production of hydrogen and oxygen through the electrolysis of seawater, further enhancing its eco-friendly credentials.
NEOS Surgery S.L. is a Barcelona-based company specializing in the research, design, development, and commercialization of implantable medical devices for neurosurgery. Founded in 2003, NEOS focuses on innovative solutions for cranial and spinal surgical applications, including its proprietary BHID cranial fixation system, which is designed for placement in the burr hole of a craniotomy. The company is committed to meeting the needs of neurosurgeons and patients, ensuring its products are both effective and compliant with stringent quality standards, including ISO certifications. By capturing market demands, NEOS aims to create high-value medical devices that enhance surgical outcomes and contribute to advancements in the neurosurgery field.
X1 Wind is a disruptive floating platform developing a floating wind platform for deep waters. The platform has redesigned floating wind platforms to reduce costs by 50percent and weight 80percent while expanding the operation depth range in comparison to other floating solutions. It has less active systems than current designs and can be fully assembled at the port and then installed using a small tug boat. X1 Wind helps to achieve a radical weight reduction in floating wind structures to current semi-submersible and spar systems. It was founded in 2017 and is based in Barcelona, Spain.
X1 Wind is a disruptive floating platform developing a floating wind platform for deep waters. The platform has redesigned floating wind platforms to reduce costs by 50percent and weight 80percent while expanding the operation depth range in comparison to other floating solutions. It has less active systems than current designs and can be fully assembled at the port and then installed using a small tug boat. X1 Wind helps to achieve a radical weight reduction in floating wind structures to current semi-submersible and spar systems. It was founded in 2017 and is based in Barcelona, Spain.
Unblur is a technology company based in Barcelona, Spain, founded in 2015, that focuses on developing AI software for public emergency services, including firefighters, civil protection, and police. Its primary offering is IRIS, a modular software-as-a-service platform designed to enhance incident command. The platform centralizes data and tools, providing incident commanders with real-time situational awareness throughout the various stages of an incident. This capability enables emergency service organizations to improve their operational response and make informed decisions during critical situations, ultimately enhancing coordination among teams and effectiveness in emergency management.
Unblur is a technology company based in Barcelona, Spain, founded in 2015, that focuses on developing AI software for public emergency services, including firefighters, civil protection, and police. Its primary offering is IRIS, a modular software-as-a-service platform designed to enhance incident command. The platform centralizes data and tools, providing incident commanders with real-time situational awareness throughout the various stages of an incident. This capability enables emergency service organizations to improve their operational response and make informed decisions during critical situations, ultimately enhancing coordination among teams and effectiveness in emergency management.
Ability Pharmaceuticals, S.L. is a clinical stage biopharmaceutical company based in Barcelona, Spain, dedicated to the discovery and development of human therapeutics for cancer and other unmet medical needs. The company specializes in creating Lipid Analogue Therapeutics, a novel class of small molecules designed to be administered orally. Its primary focus is on developing treatments for lung, pancreatic, and gynecological cancers. The development pipeline includes ABTL0812, which targets the Akt/mTOR signaling pathways, and ABTL0815, currently in preclinical characterization. Ability Pharmaceuticals develops its drug candidates up to clinical proof of concept before out-licensing them to pharmaceutical companies for further development. Founded in 2009, the company was formerly known as AB Therapeutics, S.L. and changed its name in September 2012.
Revolutionary electromagnetic endoscopy accessory to automatize polyp detection
Revolutionary electromagnetic endoscopy accessory to automatize polyp detection
SOMAprobes S.L. develops healthcare technology for magnetic resonance imaging detection of bacterial pathogens at the onset of infectious disease. The company was incorporated in 2014 and is based in Donostia, Spain.
ADmit Therapeutics, S.L. is a biotechnology company based in Begues, Spain, dedicated to the development of diagnostic tests for the early detection of Alzheimer’s disease. Founded in 2017, the company utilizes epigenetic analysis of blood samples to identify a series of mitochondrial biomarkers that are not related to traditional indicators such as ß-amyloid or tau proteins. By analyzing a large number of methylcytosines in mitochondrial DNA through next-generation sequencing, ADmit Therapeutics provides a novel and accessible method for medical practitioners to detect early-stage Alzheimer’s disease. Their innovative approach primarily serves pharmaceutical companies, aiming to enhance diagnostic capabilities in the field of neurodegenerative diseases.
Cinfo specializes in cloud-based automated video production services that cater to various enterprises equipped with venues and broadband connections. The company installs smart cameras at these venues, allowing for the creation and broadcasting of high-quality videos, either live or on-demand, to a range of devices including mobile phones, web browsers, smart TVs, and virtual reality platforms. Cinfo's technology enhances viewer experiences through multi-camera setups and immersive virtual reality capabilities while also providing valuable tools for sports organizations and coaches to analyze training footage and improve competitions. Beyond sports, Cinfo's systems have been adopted in sectors such as aeronautics and corporate communications, where they serve to stream IoT data and facilitate multi-country management and press conferences, respectively.
ZUMA is an innovative company dedicated to the development of high-end mechatronic systems for the bicycle industry. With a strong foundation in research and industrial experience, the company focuses on addressing market-level challenges by enhancing bicycles with advanced features and capabilities. As the bicycle market shifts from purely mechanical models to integrated mechatronic systems, ZUMA aims to elevate the potential of bicycles for both leisure and transportation. The company specializes in the design and manufacture of reliable electronic chainring shifters that enable sequential operation and offer a wider range of transmissions with smaller jumps. Additionally, ZUMA produces a lightweight rear MTB cassette that enhances pedaling dynamics for cyclists. The ultimate goal is to establish ZUMA as a leading reference in the industry by offering unique and differentiated products.
Cinfo specializes in cloud-based automated video production services that cater to various enterprises equipped with venues and broadband connections. The company installs smart cameras at these venues, allowing for the creation and broadcasting of high-quality videos, either live or on-demand, to a range of devices including mobile phones, web browsers, smart TVs, and virtual reality platforms. Cinfo's technology enhances viewer experiences through multi-camera setups and immersive virtual reality capabilities while also providing valuable tools for sports organizations and coaches to analyze training footage and improve competitions. Beyond sports, Cinfo's systems have been adopted in sectors such as aeronautics and corporate communications, where they serve to stream IoT data and facilitate multi-country management and press conferences, respectively.
Manufacturer of a self-climbing crane (craneless technology) to change the major components of wind turbines. The company designs and manufactures lifting equipment that enables the exchange of blades and generators in wind turbine generators, onshore and offshore, without the need for a high-tonnage crane and focuses on designing innovative and creative craneless solutions for the wind energy sector, specifically a self-climbing crane enabling clients to lift up a load of heavyweight and place it on inaccessible surfaces or areas.
Ability Pharmaceuticals, S.L. is a clinical stage biopharmaceutical company based in Barcelona, Spain, dedicated to the discovery and development of human therapeutics for cancer and other unmet medical needs. The company specializes in creating Lipid Analogue Therapeutics, a novel class of small molecules designed to be administered orally. Its primary focus is on developing treatments for lung, pancreatic, and gynecological cancers. The development pipeline includes ABTL0812, which targets the Akt/mTOR signaling pathways, and ABTL0815, currently in preclinical characterization. Ability Pharmaceuticals develops its drug candidates up to clinical proof of concept before out-licensing them to pharmaceutical companies for further development. Founded in 2009, the company was formerly known as AB Therapeutics, S.L. and changed its name in September 2012.
Orbital Advertising, S.L. operates a platform designed to assist companies and agencies in creating, managing, and optimizing advertisements across various platforms and languages. Established in 2016 and based in Madrid, Spain, the company offers tools for automatic real-time campaign management, which helps identify opportunities to reduce costs and enhance results. Its platform includes a campaign monitoring dashboard that enables users to analyze online campaign performance and refine strategies as needed. Additionally, OrbitalAds provides a language-agnostic solution that streamlines keyword management for Google Search campaigns, facilitating more effective decision-making and improving visibility in search results.
omni:us is a developer of insurance claims automation software that leverages advanced artificial intelligence and natural language processing to enhance the efficiency of claims processing. The omni:us Platform allows insurers to create customized modules and swiftly integrate AI into their operations through the Cognitive Claims Kit, which addresses various use cases along the claims value chain, including document intake and coverage verification. The software is designed to work seamlessly with legacy systems, requiring no in-house AI expertise for implementation. By utilizing handwritten text recognition technology, omni:us automates data-intensive workflows and generates comprehensive claims profiles. The company aims to foster a hybrid workflow where human and machine collaboration enhances productivity. Headquartered in Berlin, omni:us has a research partnership in Barcelona and maintains a presence in the UK, France, and the United States, serving clients such as Allianz, Baloise, and AmTrust.
Nanoker Research is a SME-company founded in 2011 with the aim to achieve the commercial exploitation of the research results generated in the European Integrated Project IP NANOKER “Structural ceramic nanocomposites for top-end functional applications” (515784. FP6-NMP). This project was focused on the development of several families of a new generation of nanostructured ceramic materials with potential application in different market sectors. Nanoker joined together professionals with more than 20 years of experience in the production and development of technical ceramics with entrepreneurs from academia with a deep knowledge on nanoceramics and nanocomposites. Nanoker Research, S.L. produces and commercializes high performance ceramic components based on advanced ceramics, nanoceramics and nanocomposites for industrial and biomedical applications. Nanoker Research, S.L. focuses its activity in the field of technical ceramics for industrial applications through the trademark Keratec Advanced Materials whereas produces and commercializes biomedical products through the company Bioker Research, S.L.